Spearhead Capital Advisors’s Editas Medicine EDIT Stock Holding History

Spearhead Capital Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-7,715	Closed	-$317K	–	181
2021 Q3	$317K	Sell	7,715 -334	-4%	-$18.3K	0.04%	147
2021 Q2	$456K	Sell	8,049 -377	-4%	-$13.9K	0.06%	121
2021 Q1	$354K	Buy	8,426 +399	+5%	+$22.7K	0.05%	119
2020 Q4	$563K	Sell	8,027 -928	-10%	-$38.1K	0.09%	90
2020 Q3	$251K	Hold	8,955	–	–	0.05%	155
2020 Q2	$265K	Buy	+8,955	New	+$234K	0.06%	121
2020 Q1	–	Sell	-9,985	Closed	-$296K	–	117
2019 Q4	$296K	Buy	+9,985	New	+$249K	0.07%	78

Other funds holding EDIT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Spearhead Capital Advisors's EDIT Position: Q4 2021 in Review

Spearhead Capital Advisors sold out of Editas Medicine (EDIT) in Q4 2021, closing a stake of 7,715 shares — an estimated $317K sold.

Spearhead Capital Advisors first reported a position in EDIT in Q4 2019 and held it in 7 quarters. The position peaked at $563K in Q4 2020. 305 funds tracked by Wall St. Rank hold EDIT as of Q4 2021.

Spearhead Capital Advisors reported no remaining Editas Medicine position as of Q4 2021 after selling out during the quarter.
Spearhead Capital Advisors sold 7,715 Editas Medicine shares in Q4 2021, an estimated $317K.
Spearhead Capital Advisors first reported a position in Editas Medicine in Q4 2019 and held it in 7 quarters.
Spearhead Capital Advisors's Editas Medicine position peaked at $563K in Q4 2020.
305 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2021.

Based on Spearhead Capital Advisors's 13F filing for Q4 2021, filed 25 Jan 2022.